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Reelin is a glycoprotein that plays a critical role in the regulation of neuronal migration during brain
development and, since reelin has a role in the control of cell migration, it might represents an important factor
in cancer pathology. In this study, 66 surgical specimens of prostate cancer were analyzed for reelin expression
by immunohistochemical method. The reelin expression was correlated with Gleason score and individual
Gleason patterns. Reelin expression was found in 39% prostate cancers. Stromal tissues, normal epithelial cells
and prostate intraepithelial neoplasia (PIN) of any grade around and distant from cancer were always negative
for reelin. Reelin was found in malignant prostatic epithelial glands of 50% cases Gleason score 10, 52%
Gleason score 9, 56% Gleason score 8, 18% Gleason score 7, while no sample of prostate cancers with Gleason
score 6 showed reelin expression (P¼ 0,005). As reelin staining is frequently found in high Gleason score
prostate cancers, we explored whether reelin expression is influenced by single Gleason patterns. While
Gleason 3 pattern did not show reelin immunoreactivity, reelin expression was found in 35% Gleason 4 patterns
and 45% Gleason 5 patterns (Po0.001). Our results demonstrated for the first time that reelin is expressed in
prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and
correlates significantly with increasing of single Gleason patterns. This suggests reelin may behave as a
specific histological marker and may represent a useful biomarker to predict aggressive phenotypic behavior of
prostatic cancer cells.
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Reelin is a 420 kDa secreted extracellular glycopro-
tein that plays a critical role in the regulation of
neuronal migration during brain development.1
Reelin is thought to guide migrating neurons by
interacting with two cell surface receptors, very low
density lipoprotein receptor (VLDLR) and apolipo-
protein E receptor 2 (ApoER2), and by activating a
tyrosine kinase signalling cascade that instructs
neurons to reach their correct laminar position in
the cortex;2 reelin modulates the cytoskeletal orga-
nization and behavior of migrating neurons by
regulating the phosphorylation state of the micro-
tubule-stabilizing protein tau; mice that are mutant
for reelin show high levels of tau phosphorylation
suggesting that defective reelin signalling leads to
tau hyperphosphorylation.3 Although most studies
have focused on the role of reelin in central neural
system (CNS) development, recent data have shown
that reelin is also expressed in adult peripheral
tissues, including the peripheral neural system,4
liver, kidney, testis, ovary,5 odontoblasts,6 plasma
cells,7 serum,8 acinar and ductal pancreatic epithe-
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lial cells, Langherhans islet cells and autonomic
peripheral nerves,9 thereby proposing a wide spec-
trum of biological functions.
Although reelin dysfunction has been implicated
in the pathogenesis of brain malformation and
several psychiatric disorders,10 its biological role
in the development and function of other organs
remains obscure. As reelin has a role in the control
of cell migration, it might represents an important
factor in cancer invasion and metastasis.
Wetmore et al11 demonstrated for the first time
reelin expression in cancer pathology reporting the
presence of reelin mRNA in mice medulloblastoma
tissue.
Reelin expression in non-cerebral tumor pathol-
ogy has also been reported by immunohistochemical
methods in esophageal12 and pancreatic9 cancer.
In order to further understand the role of reelin in
neoplastic pathology, we initially investigated reelin
expression by immunohistochemistry in a large
series of most frequent human cancers (skin, color-
ectal, gastric, neuroendocrine, breast, prostate). In
this initial study, reelin expression was found only
in two prostate cancers. This finding led us to
further investigate reelin expression in a larger
series of prostate cancers.
Materials and methods
Case Selection
Reelin expression was evaluated in ten skin, color-
ectal, gastric, breast, neuroendocrine tumors and
prostate cancer resection specimens (total of 60
cases), retrieved from the files of the Surgical
Pathology Unit of the University Campus Bio-
Medico. Tissue samples were fixed in 4% neutral
buffered formaldehyde and embedded in paraffin.
Routine hematoxylin- and eosin-staining was per-
formed on the sections for histopathologic evalua-
tion. Tumor histology and grade were evaluated at
primary diagnosis and extracted from the pathology
reports. They were re-evaluated according to the
International Union Against Cancer.13 Consecutive
3mm sections were cut from samples used for
routine diagnostic purposes. Reelin expression was
evaluated by immunohistochemical methods.
According to the initial immunohistochemical
results, another 56 prostate cancer cases were
further selected from the files of the Surgical
Pathology Unit of the University Campus Bio-
Medico and the Institute of Pathology of the
University of Palermo. No patient had received
chemotherapy, hormonotherapy or radiation therapy
before surgery.
One of the pathologists (MZ) re-examined the
hematoxylin- and eosin-stained slides, classified the
tumors according to commonly used criteria13 and
representative blocks were chosen for reelin im-
munohistochemical evaluation. Within the 66 pros-
tate cancer cases studied, 31 were radical
prostatectomies, 19 enucleations and 16 TURPs.
The Gleason score findings are reported in Table 2.
High-grade prostatic intraepithelial neoplasia (PIN),
the direct precursor of prostate cancer, was present
in 31 of the 66 prostate cancers included in this
study. For reelin immunohistochemical evaluation,
3mm sections were cut from the paraffin blocks
corresponding to the slides selected.
Antibodies and Reagents
Unless otherwise stated, all reagents were from
DakoCytomation Inc. (Carpinteria, CA, USA). In
the present study, two primary antibodies against
reelin protein were used: the mouse monoclonal
antibody (Calbiochem: 142 clone; 1/500) that recog-
nizes an epitope localized in the N-terminal region
of reelin14 and, to confirm the specificity of reelin
staining, 10 randomly select cases of prostate cancer
were immunostained with the rabbit polyclonal
antibody (Santa Cruz: H-221 clone; 1/200) that
recognizes an epitope localized in the C-terminal
region of reelin.15
Immunohistochemical Staining
Immunohistochemical staining was performed by
the streptavidin–biotin method. In brief, sections
were deparaffinized and endogenous peroxidase
activity was blocked by incubating the sections in
3% hydrogen peroxide. The slides were washed
with TBS, treated with horse serum for 30 min at
room temperature to block non-specific binding,
incubated with the anti-reelin mouse monoclonal
(142 clone) and rabbit polyclonal (H-221 clone)
antibodies for 2 h at room temperature. After wash-
ing three times with TBS (5 min each wash), sections
were incubated with a biotinylated anti-mouse/anti-
rabbit (LSAB2) antibody for 10 min. They were then
washed three times with in TBS, treated with
streptavidin–biotin–peroxidase complex for 10 min
and then washed again with TBS for three times.
Finally, specimens were incubated with 3,30-diami-
nobenzidine (DAB) for 3 min, followed by hematox-
ylin counterstaining. All the sections were
examined by light microscopy by two investigators
(GP and DL) blind to the corresponding clinico-
pathological data to assess the presence or absence
of reelin immunostaining and its distribution.
Neural structures (fibres and ganglion) present in
the tissue sections were used as positive internal
control.9 As negative control some slides were
processed without primary antibody and were
included in each staining run.
Reelin immunostaining was evaluated in terms of
the percentage of reelin immunoreactive cells over a
total of at least 1000 tumor cells. Only prostate
cancers with a percentage of immunostained cells
Z10% were considered as positive.
npg_Mpath_3800743
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We evaluated reelin expression by assessing
immunostaining in the various Gleason patterns in
addition to Gleason score.
Statistic Methods
Reelin expression between different Gleason score
and different Gleason patterns were compared using
logistic regression analysis. Spearman’s rank corre-
lation test was used to assess relationships between
ordinal data. Po0.05 were regarded as statistically
significant in tailed tests. SPSS software (version
13.00, SPSS, Chicago) was used for statistical
analysis.
Results
Reelin Expression in Different Cancer Types
Among the different cancers studied in the initial
analysis, only two prostate cancers resulted positive
for reelin. Table 1 summarizes the principal patho-
logical characteristics of these neoplastic lesions.
Stromal tissue, vascular structures, normal epithe-
lial cells did not show reelin expression. On the
contrary, neural structures were positively stained
for reelin. In particular, ganglia showed cytoplasmic
staining for reelin.
On the basis of these preliminary results, reelin
expression was further evaluated in a larger series of
prostate cancers.
Reelin Expression in Prostate Cancer
Another 56 prostate cancers were selected on the
basis of the corresponding Gleason score and were
processed by immunohistochemistry for reelin ex-
pression.
Stromal tissues and normal glandular epithelial
cells around and distant from the cancer were
always negative for reelin. All prostate intraepithe-
lial neoplasia (PIN) lesions of any grades were also
negative. The neural structures present in the
sections examined were positively stained for reel-
in, thus were used as internal positive control
(Figure 1).
Of a total of 66 cases, 26 (39%) prostate cancers
showed reelin expression. Table 2 reports the
Gleason score and the immunohistochemical find-
ings obtained with anti-reelin clone 142 antibody of
all prostate cancers studied. Reelin expression was
evenly distributed throughout the cancer in those
cases with heterogeneous staining. Any difference
in staining relating to the different types of tissue
examined was found (data not shown). Furthermore,
no difference in terms of reelin expression was
found among cytoarchitectural patterns.
Similar immunohistochemical results were ob-
tained with the two different antibodies (142 clone
and H-221 clone) showing a clear cytoplasmic
positivity for reelin in malignant neoplastic cells
(data not shown).
npg_Mpath_3800743
Table 1 Preliminary study on reelin expression in cancer pathology
Cancer lesions No. Histotype No. Grade No. No. of reelin positive tumors
Skin 10 Basal cell 5 5 0
Squamous cell 5 Low 3 0
High 2 0
Colorectal 10 Adenocarcinoma 10 Moderate 5 0
High 5 0
Gastric 10 Intestinal type 5 Low 3 0
High 2 0
Diffuse type 5 High 5 0
Breast 10 Ductal 5 Low 3 0
High 2 0
Lobular 5 High 5 0
Neuroendocrine 10 Gastric 4 4 0
Duodenum 2 2 0
Appendix 4 4 0
Prostate 10 Adenocarcinoma 10 Gleason 6 2 0
Gleason 7 2 0
Gleason 8 2 0
Gleason 9 2 1
Gleason 10 2 1
Q1
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Relationship between Reelin Expression and Gleason
Score
Of 66 prostate cancers, 10 (15%) specimens were
categorized as Gleason score 6, 11 (17%) as Gleason
score 7, 18 (27%) as Gleason score 8, 23 (35%) as
Gleason score 9 and 4 (6%) as Gleason score 10.
Reelin expression was found in malignant pro-
static epithelial glands of 2/4 (50%) cases Gleason
score 10, 12/23 (52%) Gleason score 9, 10/18 (56%)
Gleason score 8, 2/11 (18%) Gleason score 7, while
no sample of prostate cancers with Gleason score 6
showed reelin expression.
With the logistic regression analysis, a significant
statistical difference was detected among Gleason
scores as it concerns reelin expression (P¼ 0.005),
suggesting that reelin expression is modified by
differentiation grade (Table 3).
The Gleason score is the sum of the two most
frequently occurring Gleason patterns within the
same prostate specimen.16
As reelin staining is frequently found in high
Gleason score prostate cancers, we explored
whether reelin expression is influenced by single
Gleason patterns.
npg_Mpath_3800743
Figure 1 (a) Immunohistochemical analysis of reelin expression (Mab 142) in a prostate specimen with a Gleason 8(4þ 4) cancer. (b–e)
Details of (a). (b) PIN lesions, (c) nonneoplastic prostate epithelial cells and stromal tissue resulted negative for reelin staining in contrast
to positive labelling in a peripheral nerve tissue (arrow). Immunolabelling for reelin is identified diffusely in prostate cancer. (d) Clearly
shows the cytoplasmic staining pattern of reelin in prostate cancer at higher magnification. (e) The neural structures present in the
section were positively stained for reelin, thus were used as internal positive control. Original magnification: (a) 20; (b–e) 200.
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show reelin immunoreactivity, reelin expression
was found in 17/48 (35%) Gleason 4 patterns and
14/31 (45%) Gleason 5 patterns (Figure 2). Also the
difference in terms of reelin expression within
different Gleason patterns resulted statistical sig-
nificant (Po0,001) (Table 4). Furthermore, in this
context, a highly positive statistical correlation was
found between the percentage of reelin positive cells
and the Gleason pattern (rho: 0.372; Po0.0001).
This finding suggests that reelin expression in
higher Gleason scores is a result of the increased
expression of reelin associated with an increased
Gleason pattern.
Discussion
Reelin is a large protein of the extracellular matrix
that plays an important role in the lamination of
several brain structures during the cortical develop-
ment.17,18 Recently, it was demonstrated that reelin
is also expressed in organs and compartments
outside of the CNS4–7,9 where it might regulate
cellular differentiation and cellular migration. As
these processes participate in neoplastic transforma-
tion and progression, we investigated reelin expres-
sion in a large series of neoplastic lesions and report
for the first time reelin expression in prostate
cancers.
In our study, we observed 39% prostate cancers
showing reelin expression. Stromal tissues and
normal glandular epithelial cells around and distant
npg_Mpath_3800743
Table 2 Gleason grade and Gleason patterns of all prostate
cancers studied and immunohistochemical findings obtained
with anti-reelin clone 142 antibody
No. Age Primary
Gleason
pattern
% of reelin
positive cells
on primary
Gleason
Secondary
Gleason
pattern
% of reelin
positive cells
on
secondary
Gleason
Gleason
score
1 71 5 43 — — 10
2 58 5 71 — — 10
3 75 5 0 — — 10
4 68 5 0 — — 10
5 85 5 59 4 51 9
6 81 5 21 4 0 9
7 59 5 46 4 0 9
8 74 5 0 4 0 9
9 62 5 0 4 0 9
10 56 5 5 4 0 9
11 66 5 85 4 0 9
12 77 5 89 4 10 9
13 61 5 72 4 0 9
14 66 5 0 4 0 9
15 73 4 0 5 0 9
16 76 4 0 5 77 9
17 65 4 0 5 0 9
18 71 4 0 5 0 9
19 65 4 0 5 0 9
20 73 4 0 5 75 9
21 78 4 0 5 0 9
22 54 4 71 5 73 9
23 74 4 0 5 0 9
24 78 4 41 5 0 9
25 65 4 0 5 0 9
26 81 4 52 5 55 9
27 70 4 37 5 29 9
28 70 5 0 3 0 8
29 75 5 0 3 0 8
30 73 5 49 3 0 8
31 74 3 0 5 0 8
32 62 4 0 — — 8
33 66 4 58 — — 8
34 76 4 0 — — 8
35 77 4 92 — — 8
36 80 4 89 — — 8
37 68 4 0 — — 8
38 72 4 49 — — 8
39 64 4 53 — — 8
40 68 4 0 — — 8
41 80 4 20 — — 8
42 80 4 43 — — 8
43 77 4 62 — — 8
44 75 4 0 — — 8
45 59 4 34 — — 8
46 63 4 57 3 0 7
47 70 4 0 3 0 7
48 54 4 0 3 0 7
49 64 4 0 3 0 7
50 68 4 0 3 0 7
51 81 4 5 3 0 7
52 62 3 0 4 3 7
53 67 3 0 4 0 7
54 66 3 0 4 0 7
55 68 3 0 4 0 7
56 68 3 0 4 54 7
57 57 3 0 — — 6
58 75 3 0 — — 6
59 64 3 0 — — 6
60 75 3 0 — — 6
61 66 3 0 — — 6
62 68 3 0 — — 6
63 68 3 0 — — 6
Table 2 Continued
No. Age Primary
Gleason
pattern
% of reelin
positive cells
on primary
Gleason
Secondary
Gleason
pattern
% of reelin
positive cells
on
secondary
Gleason
Gleason
score
64 71 3 0 — — 6
65 61 3 0 — — 6
66 72 3 0 — — 6
Table 3 Regression analysis between Gleason score and reelin
expression
Reelin expression Total (%)
Gleason grade
6 0 (0) 10
7 2 (18) 11
8 10 (56) 18
9 12 (52) 23
10 2 (50) 4
Total 26 (40) 66
Logistic regression: odds ratio¼ 2.136; P¼ 0.005.
Reelin expression in prostate cancer
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from cancer were always negative for reelin. PIN
lesions of any grade were also reelin negative. The
neural structures present within the tissue exam-
ined sections showed a positive immunoreactivity
for reelin, thus were used as an internal positive
control.9 According to our results reelin is expressed
specifically in cancer lesions while it does not show
up in normal and hypertrophic tissue. Reelin is not
also expressed in PIN lesions, thus suggesting it
behaves as a specific histological marker for prostate
cancer.
Our results are consistent with another recent
report about reelin expression in cancer pathology.
Wang et al12 found reelin expression in esophageal
cancer through RT-PCR and immunohistochemical
analysis on normal and tumor esophageal tissue.
Low expression of reelin was detected in all normal
esophageal tissues, while increased expression and
strong immunoreactivity for reelin was detected in
87,5% of esophageal carcinoma tissues studied.
Furthermore, Sato et al9 have recently demon-
strated the expression of reelin protein in primary
pancreatic cancers by immunohistochemical experi-
ments performed using tissue microarrays on a large
series of primary pancreatic adenocarcinomas and
corresponding nonneoplastic pancreatic tissues. Of
294 primary pancreatic cancers, 28% showed
diffuse immunolabeling for reelin. In nonneoplastic
pancreas, immunolabeling for reelin was identified
in the cytoplasm of various cell types, including
normal ductal epithelial cells, acinar cells, islet
cells, and autonomic peripheral nerves. Moreover
they demonstrated that reelin is a frequent target for
epigenetic silencing in pancreatic neoplasms, and
loss of reelin function can confer a more aggressive
phenotype to pancreatic cancer cells, thus showing
an association between reelin expression and the
progression of cancer.
In the present study, we show that an increase of
reelin expression is more frequently associated with
higher Gleason scores of prostate cancers. The
results of our study, in agreement with the other
reports, are consistent with the hypothesis that
reelin may play a key role in cancer pathology.
Moreover, prostate cancer is the leading cause of
death due to malignancy, accounting for 40% of all
cancers diagnosed in men, and the frequency of all
forms of the disease increases with age.19 The early
detection of molecular changes which are predictive
of invasiveness and metastatic behavior is essential
to clinical decision-making. Interestingly, in our
study, a positive statistical correlation was found
between reelin expression and Gleason score.
Gleason grading is the most widely used patholo-
gical grading system in patients with prostate
cancer.16 Although Gleason grading is commonly
used as a predictor of disease progression, it is
limited by lack of total accuracy in distinguishing
patients at risk of disease progression from patients
with stable disease. The 20-year prostate cancer
mortality rate for patients with Gleason 5, 6, 7 and
8–10 is 14, 27, 45 and 66% respectively, suggesting
that each Gleason score consists of an heterogeneous
population of patients with both progressive and
stable forms of disease.20 Therefore, there is a clear
npg_Mpath_3800743
Figure 2 Immunohistochemical analysis of reelin in prostate cancer. (a) Gleason 3 pattern did not show reelin immunoreactivity. The
neural structures present in the section were positively stained (arrow), which serve as an internal control. Reelin immunoreactivity was
found in 35% Gleason 4 (b) and in 45% Gleason 5 pattern (c). Original magnification: (a–c) 200.
Table 4 Regression analysis between differ ent Gleason patterns
and reelin expression
Reelin expression Total (%)
Gleason pattern
3 0 (0) 25
4 17 (35) 48
5 14 (45) 31
Total 31 (30) 104
Logistic regression: odds ratio¼3.266; P¼ 0.001.
Reelin expression in prostate cancer
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need to identify novel biomarkers that can further
improve or predict clinical progression in addition
to the Gleason scoring system. Our predictive
capability of prostate cancer incidence, recurrence
following treatment and disease progression has
improved since the introduction of validated nomo-
grams, which use multiple continuous variables for
prediction.21 In addition to clinical parameters such
as tumor grade and stage, serum PSA and other
serum and tissue molecular markers, such as
interleukin receptor 6 and transforming growth
factor b1, are now being included in experimental
nomograms to improve the predictive accuracy.22
Since the present study demonstrates that reelin
expression correlates significantly with increasing
Gleason score, it is conceivable that reelin may
represent a useful biomarker to predict aggressive
phenotypic behavior of prostatic cancer cells and
thus may be potentially incorporated in future
nomograms.
Besides demonstrating reelin expression in high-
grade prostate cancers, we have also shown that
reelin occurs more frequently inZGleason 4 pattern
compared to Gleason 3 pattern prostate cancer.
There is a debate in the urologic community with
regard to the clinical significance of individual
Gleason patterns within the total Gleason scoring
system.23 For example, patients with a Gleason score
7 which show a Gleason score 4þ 3 tend to have
higher biochemical recurrence rate than patients
with a Gleason score 3þ 4, suggesting that an
individual Gleason pattern can also represent an
independent predictor of disease progression.24 Our
study confirms that reelin expression occurs at
significantly higher rate in Gleason patterns 4 or 5
compared to Gleason patterns 3, which suggests that
reelin could be a novel biomarker for high Gleason
patterns. The finding that reelin expression differs
significantly between Gleason patterns 3 and 4
suggests an association of reelin with a more
aggressive malignant phenotype. Characteristic gene
expression patterns characteristically associated
with specific Gleason scores have already been
shown for prostate cancers.25
As reelin is involved in the control of cell
migration and the latter represents an important
factor in cancer invasion and metastasis, further
research on the role of reelin in prostate cancer may
be helpful to understand the molecular mechanisms
of prostate cancer aggressiveness and may provide a
new target for diagnosis, prognosis and therapy of
prostate carcinoma.
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